ATE290398T1 - Verwendung von alpha-1 antichymotrypsin zur herstellung von einer zusammensetzung zur behandlung, vorbeugung oder diagnose von schwerheilenden diabätische wunden - Google Patents

Verwendung von alpha-1 antichymotrypsin zur herstellung von einer zusammensetzung zur behandlung, vorbeugung oder diagnose von schwerheilenden diabätische wunden

Info

Publication number
ATE290398T1
ATE290398T1 AT02724304T AT02724304T ATE290398T1 AT E290398 T1 ATE290398 T1 AT E290398T1 AT 02724304 T AT02724304 T AT 02724304T AT 02724304 T AT02724304 T AT 02724304T AT E290398 T1 ATE290398 T1 AT E290398T1
Authority
AT
Austria
Prior art keywords
antichymotrypsin
diagnosis
alpha
prevention
treatment
Prior art date
Application number
AT02724304T
Other languages
English (en)
Inventor
Joern-Peter Halle
Andreas Goppelt
Peter Hof
Original Assignee
Switch Biotech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10121255A external-priority patent/DE10121255A1/de
Application filed by Switch Biotech Ag filed Critical Switch Biotech Ag
Application granted granted Critical
Publication of ATE290398T1 publication Critical patent/ATE290398T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT02724304T 2001-04-30 2002-04-30 Verwendung von alpha-1 antichymotrypsin zur herstellung von einer zusammensetzung zur behandlung, vorbeugung oder diagnose von schwerheilenden diabätische wunden ATE290398T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10121255A DE10121255A1 (de) 2001-04-30 2001-04-30 Verwendung von alpha 1-Antichymotrypsin Polypeptiden oder diese kodierende Nukleinsäuren, oder einer ein ACT Polypeptid oder diese kodierende Nukleinsäure exprimierende Zelle, zur Behandlung und/oder Prävention von diabetes-assoziierten und/oder arteriellen schlecht heilenden Wunden und zur Identifizierung von pharmakologisch aktiven Substanzen
US32334801P 2001-09-18 2001-09-18
PCT/EP2002/004757 WO2002088180A2 (en) 2001-04-30 2002-04-30 Use of alpha 1-antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic or arterial wounds

Publications (1)

Publication Number Publication Date
ATE290398T1 true ATE290398T1 (de) 2005-03-15

Family

ID=26009207

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02724304T ATE290398T1 (de) 2001-04-30 2002-04-30 Verwendung von alpha-1 antichymotrypsin zur herstellung von einer zusammensetzung zur behandlung, vorbeugung oder diagnose von schwerheilenden diabätische wunden

Country Status (8)

Country Link
EP (2) EP1568376B1 (de)
JP (2) JP4384855B2 (de)
AT (1) ATE290398T1 (de)
AU (1) AU2002254999B2 (de)
CA (1) CA2446197C (de)
DK (1) DK1392354T3 (de)
ES (1) ES2239715T3 (de)
WO (1) WO2002088180A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1415664A1 (de) * 2002-10-30 2004-05-06 Switch Biotech Aktiengesellschaft Verwendung von Alpha-1-antichymotrypsin in Kombination mit Alpha-1-antitrypsin zur Behandlung/Vorbeugung von schlecht heilenden arteriellen oder diabetischen Wunden
EP1666075A1 (de) 2004-10-04 2006-06-07 Switch Biotech Aktiengesellschaft Wundverband zur Freisetzung von Proteaseinhibitoren
CN101563597A (zh) * 2006-09-01 2009-10-21 美国菌种保藏中心 用于诊断和治疗2型糖尿病的组合物和方法
EP2957283B1 (de) 2014-06-19 2022-12-21 Symrise AG Verfahren zur Identifizierung von Medikamenten zur Beschleunigung der Wundheilung
WO2022111793A1 (en) 2020-11-24 2022-06-02 Symrise Ag Medicament for accelerated wound healing
WO2022161593A1 (en) 2021-01-26 2022-08-04 Symrise Ag Medicament for accelerated wound healing

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US5008242A (en) * 1986-12-24 1991-04-16 John Lezdey Treatment of inflammation using 1-antichymotrypsin
US5674708A (en) * 1989-06-23 1997-10-07 Trustees Of The University Of Pennsylvania α-1-antichymotrypsin analogues having elastase inhibitory activity
US5723316A (en) * 1989-06-23 1998-03-03 Trustees Of The University Of Pennsylvania α-1-antichymotrypsin analogues having chymase inhibiting activity
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
EP0546101A1 (de) * 1990-08-24 1993-06-16 The President And Fellows Of Harvard College Verfahren zur störung der bildung des alpha-antichymotrypsin-beta-protein-komplexe und synthetische peptide zur verwendung dabei
EP0512090B2 (de) * 1990-10-16 2006-11-22 Sonoran Desert Chemicals LLC Behandlung von entzündungen
US5698765A (en) 1991-12-02 1997-12-16 The Ontario Cancer Institute Mouse having a disrupted CD4 gene
WO1993018144A1 (en) 1992-03-05 1993-09-16 The Trustees Of Columbia University Of The City Of New York Recombination activating gene deficient animal
US5625122A (en) 1992-04-24 1997-04-29 The Ontario Cancer Institute Mouse having a disrupted lck gene
US5422244A (en) * 1992-05-05 1995-06-06 Athena Neurosciences, Inc. Detection of brain α1-antichymotrypsin
JP3741447B2 (ja) 1992-10-23 2006-02-01 中外製薬株式会社 エンドセリン−１遺伝子の機能が欠損したマウス
DE19625049A1 (de) 1996-06-22 1998-01-02 Inst Pflanzengenetik & Kultur Transgenes, nicht-menschliches Säugetier, das ein zusätzliches DNA-Reparaturgen enthält

Also Published As

Publication number Publication date
EP1568376A3 (de) 2005-10-05
EP1392354B1 (de) 2005-03-09
ES2239715T3 (es) 2005-10-01
CA2446197A1 (en) 2002-11-07
JP2005508137A (ja) 2005-03-31
CA2446197C (en) 2011-12-13
EP1392354A2 (de) 2004-03-03
EP1568376A2 (de) 2005-08-31
JP4384855B2 (ja) 2009-12-16
JP2008283966A (ja) 2008-11-27
DK1392354T3 (da) 2005-07-04
WO2002088180A2 (en) 2002-11-07
EP1568376B1 (de) 2012-11-21
WO2002088180A3 (en) 2003-04-24
AU2002254999B2 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
DE69940888D1 (de) Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie
ATE295414T1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
DE69926731D1 (de) Diagnose und behandlung von aur1 und/oder aur2 verwandten erkrankungen
ATA14642003A (de) Impfstoff für die alzheimer-krankheit
Botta et al. Effect of dental tissue conditioners and matrix metalloproteinase inhibitors on type I collagen microstructure analyzed by Fourier transform infrared spectroscopy
DE60333963D1 (de) Zytokin Ligand zur Behandlung von Asthma und Atemwegsüberreaktivität
NO1996007I1 (no) Human koagulasjons faktor VII (FVII)
ATE127853T1 (de) Verfahren zur bestimmung der funktionellen wirkung von freiem protein s oder protein c in einer plasmaprobe.
Lee et al. Hepatocyte growth factor (HGF) activator expressed in hair follicles is involved in in vitro HGF-dependent hair follicle elongation
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
ATE242005T1 (de) P277 peptidanaloge, pharmazeutische zusammenstellung davon zur behandlung und diagnose von diabetes
DE68928728D1 (de) Diagnose von retinoblastoma
ATE290398T1 (de) Verwendung von alpha-1 antichymotrypsin zur herstellung von einer zusammensetzung zur behandlung, vorbeugung oder diagnose von schwerheilenden diabätische wunden
WO2000034511A3 (de) Peptid screening test zum nachweis von ass
ATE304050T1 (de) Hbgad und higad polypeptide und nukleinsäuren und deren verwendung zur diagnose und behandlung von gad autoantigen assoziierten krankheiten
WO2002088181A3 (en) Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances
EP1281763A3 (de) Early growth response-1 (EGR-1) transkriptions-faktor
DE60140707D1 (de) GSK3-Polypeptide
DK70785D0 (da) Kompres samt fremgangsmaade til dets fremstilling
EP1132402A4 (de) Peptidfragmente mit den zelltod verhindernden aktivität
ATE395602T1 (de) Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
ATE225405T1 (de) Verfahren zur diagnose oder zur prognose von alzheimer krankheit: therapeutische zusammensetzung zur verhinderung oder zur behandlung von alzheimer krankheit
DE60203172D1 (de) Verwendung von alpha-1 antichymotrypsin zur herstellung von einer zusammensetzung zur behandlung, vorbeugung oder diagnose von schwerheilenden diabätische wunden
DE69939379D1 (de) Hemmstoff zur diagnose und behandlung von haemophilia a patienten
DE59305225D1 (de) Verfahren zur Bestimmung von Thrombose verursachenden Lupus-anticoagulant-Antikörpern

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1392354

Country of ref document: EP